113558-15-9
113558-15-9 結(jié)構(gòu)式
基本信息
寶藿苷I
寶藿苷Ⅰ
脫水淫羊藿苷)
寶藿苷I對(duì)照品,
寶藿苷I(標(biāo)準(zhǔn)品)
寶藿苷I,淫羊藿次苷Ⅱ
寶藿苷Ⅰ(分析標(biāo)準(zhǔn)品)
寶藿苷I, 來(lái)源于淫羊藿
寶藿苷I/ 淫羊藿次苷2
Icariin II
Icarisid II
Baohuside I
BaohuosideⅠ
Baohuoside-1
baohuoside I
Icariside II 113558-15-9
Baohuoside I(Icariside II)
Baohuoside I Baohuside I
物理化學(xué)性質(zhì)
制備方法
489-32-7
113558-15-9
以淫羊藿苷為原料合成5,7-二羥基-2-(4-甲氧基苯基)-8-(3-甲基-2-丁烯-1-基)-3-(((2S,3R,4R,5R,6S)-3,4,5-三羥基-6-甲基四氫-2H-吡喃-2-基)氧基)-4H-苯并吡喃-4-酮的一般步驟如下：首先，將來(lái)自瓊脂斜面（2 cm2）的C. blakesleeana菌絲體轉(zhuǎn)移至100 mL培養(yǎng)基中，于30℃、175 rpm條件下培養(yǎng)36小時(shí)，制備接種物。隨后，將10 mL接種物加入至1000 mL液體培養(yǎng)基中，并將燒瓶置于旋轉(zhuǎn)振蕩器上，在175 rpm、30℃條件下預(yù)培養(yǎng)36小時(shí)。預(yù)培養(yǎng)完成后，將100 mg淫羊藿苷溶于2 mL甲醇中，加入至2 L培養(yǎng)基中進(jìn)行制備性生物轉(zhuǎn)化，使終濃度達(dá)到50 mg/L。繼續(xù)培養(yǎng)5天后，過(guò)濾培養(yǎng)物，用等體積的EtOAc對(duì)濾液進(jìn)行五次萃取。同時(shí)，使用1000 mL EtOAc對(duì)C. blakesleeana的懸浮細(xì)胞（5.2 g）進(jìn)行提取。合并所有EtOAc萃取物，減壓濃縮。將所得殘余物（1.6 g）上樣至ODS柱（200 g，10 cm × 50 cm），以MeOH-H?O（10%至90%梯度，流速2.0 mL/min）進(jìn)行洗脫。最終，從60% MeOH洗脫的級(jí)分（500 mL）中獲得90.1 mg icariside II，純度為96.5%。
參考文獻(xiàn)：
[1] Journal of Molecular Catalysis B: Enzymatic, 2015, vol. 122, p. 141 - 146
[2] Patent: CN104530127, 2016, B. Location in patent: Paragraph 0156-0159
[3] Patent: CN104387430, 2017, B. Location in patent: Paragraph 0109; 0110; 0111; 0112
[4] Journal of Natural Products, 2008, vol. 71, # 9, p. 1513 - 1517
[5] Journal of Asian Natural Products Research, 2015, vol. 17, # 6, p. 656 - 661
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/05/22 | HY-N0011 | 寶藿苷I Baohuoside I | 113558-15-9 | 5 mg | 800元 |
| 2025/05/22 | HY-N0011 | 寶藿苷I Baohuoside I | 113558-15-9 | 10mg | 1200元 |
| 2025/05/22 | HY-N0011 | 寶藿苷I Baohuoside I | 113558-15-9 | 10mM * 1mLin DMSO | 1320元 |
常見(jiàn)問(wèn)題列表
|
CXCR4
|
Baohuoside I is an inhibitor of CXCR4, and downregulates CXCR4 expression at 12-25 μM. Baohuoside I (0-25 μM) suppresses NF-κB activation in a dose-dependent manner, suppresses CXCL12 induced the invasion of cervical cancer cells. Baohuoside I also inhibits invasion of breast cancer cells. Baohuoside I inhibits A549 cell viability, with IC 50 s of 25.1 μM at 24 h, 11.5 μM and 9.6 μM at 48 h and 72 h, respectively. Baohuoside I ((25 μM) suppresses the caspase cascade in A549 cells, elevates ROS levels and activates JNK and p38 MAPK signaling cascade. Baohuoside I (3.125, 6.25, 12.5, 25.0 and 50.0 μg/mL) significantly and dose-dependently blocks the growth of esophageal squamous cell carcinoma Eca109 cells, with an IC 50 of 4.8 μg/mL at 48 h.
Baohuoside I (25 mg/kg) decreases β-catenin protein levels, cyclin D1 and survivin expression in nude mice.